570:HKEXChina Traditional Chinese Medicine Holdings Co. Ltd. Analysis

JMC Corporation is trading at ¥400, well below its 20‑day and 50‑day SMAs of ¥407.45 and ¥401.84, and also under the 200‑day SMA of ¥425.81, indicating a price that is technically soft. The RSI sits at 47.5, the MACD histogram is negative and the MACD signal is classified as bearish, reinforcing a neutral‑to‑bearish short‑term momentum. Fundamentally, the company posted a 10.4% revenue decline and a steep –39% profit margin, with trailing EPS of –¥12.77, but forward EPS is projected at ¥43.30, suggesting a potential earnings turnaround. The forward P/E of 9.24 is far below the industry average of 29.35, and the DCF‑derived fair value of ¥989.45 implies the stock is markedly undervalued. Balance‑sheet metrics show a moderate debt‑to‑equity of 45.4% and net cash of ¥425 million against ¥748 million of debt, while ROE remains negative at –55.5%. Market sentiment is in the “Extreme Greed” zone (Fear‑Greed Index 79.45), yet the 30‑day volatility of 39% and a low beta around 0.4 point to a stock that is both volatile and relatively insulated from broader market swings.
Given the technical weakness, the current earnings loss, and the thin trading volume (average volume ≈9,000 shares versus today’s 1,300), short‑term price pressure may persist. However, the sizable valuation gap, improving forward earnings outlook, and modest leverage provide a compelling case for a medium‑ to long‑term investment thesis, provided the company can execute its turnaround and capitalize on its niche 3D‑printing and industrial CT scanner businesses.